CAMBRIDGE, Mass. & PARIS--(BUSINESS WIRE)--Dyax Corp. (NASDAQ: DYAX - News) and Fovea Pharmaceuticals, SA ("Fovea") announced today that they have entered into an exclusive license agreement for the ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results